TeamDrive
RUS
Vladimir Gurdus

Vladimir Gurdus

Founding Partner, COO

Телефоны:

+7 495 545-39-12

Send message

Vladimir is the co-founder and member of the Board of Directors of Doctor Ryadom (a private network of medical clinics). He is also the CEO and founder partner of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is Russian innovation pharmaceutical company NovaMedica LLC.

Vladimir is one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the U.S. firm Domain Associates LLC. RusnanoMedInvest was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Before assuming a key role as one of the project’s leaders and founding Team Drive, from 2007 to 2009 Vladimir was President at Medsi Group (part of AFK Sistema) and played a key role in transforming it into the leading privately-held medical service provider. Previously he had played an active role in starting up the ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding.  From 1991 to 2007 he was First Deputy CEO of ROSNO, and also the COO and CEO of ROSNO Group subsidiaries, such as ROSNO-MS. In 2006, after the acquisition of ROSNO by Allianz, Vladimir was appointed CEO of Allianz ROSNO-Life.

He is also an investor and the founder of a number of successful start-ups in the medical, insurance and IT sectors.

Vladimir is a member of the Government Expert Council of the Russian Federation. This organisation was established to involve the business community in the preparation and implementation of the decisions of the Russian Government, and also to ensure public oversight over the work of the federal authorities. Members of the Council attend the meetings of the Russian government, government and interdepartmental commissions and committees, and perform expert reviews of the draft decisions of the Russian government and federal executive agencies and the results of implementation. As a member of the Expert Council Vladimir proactively tackles issues of developing the Russian healthcare and pharmaceutical sectors. He also co-chairs a joint working group of the Expert Council and the Ministry of Health, whose chief remit is to draft the development framework of a healthcare system and the provision of the medicines required by the Russian population drug.

Vladimir is a member of the Public Council under the Ministry of Health of the Russian Federation – a permanent consultative public health oversight body.

Vladimir graduated cum laude from I.M. Sechenov Moscow Medical Academy. He has a second degree in finance and economics at RosNOU. Vladimir is a Doctor of Medical Sciences and Professor.

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more